Roche Secures Diagnostics Deal with LumiraDx for $295M
Switzerland’s pharmaceutical giant Roche (SWX: ROG) has sealed a deal to acquire innovative diagnostics technology...
January 2024
Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug
vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based...
Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment
Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first...
Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Gets US FDA Approval for Clinical Trials
Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...
CareRay Digital Medical Technology to Acquire 30% Stake in UK’s ISDI for USD 15.2 Million
CareRay Digital Medical Technology Co., Ltd, a company based in Suzhou (SHA: 688607), has announced...
Jiangsu Hengrui’s SHR-A2009 Earns Fast-Track Status for Metastatic NSCLC Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that its in-house developed antibody-drug conjugate...
Grifols Sells 20% Stake in Shanghai RAAS to Haier Group for USD 1.8 Billion
Grifols (BME: GRF; NASDAQ: GRFS), a Spanish pharmaceutical company, has announced the formation of an...
MicroPort CardioFlow Medtech to Acquire Controlling Stake in La Ronda for USD 20 Million
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
P-Cure Initiates Construction of Affordable Proton Therapy Center in China’s Shandong Province
P-Cure, an Israeli company specializing in proton therapy, has commenced construction on a proton therapy...
Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC
Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement...